---
title: "Enanta Pharma's RSV Bet And Immunology Ambitions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286895623.md"
description: "Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly."
datetime: "2026-05-19T10:34:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286895623.md)
  - [en](https://longbridge.com/en/news/286895623.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286895623.md)
---

# Enanta Pharma's RSV Bet And Immunology Ambitions

Add  as your preferred news source on Google

 Add Now

Enanta Pharmaceuticals Inc. (ENTA), a clinical-stage biotechnology company focusing on viral infections and immunological diseases, will be highlighting its investigational programs - Zelicapavir and EPS-3903 - at the American Thoracic Society (ATS) International Conference today.

**Zelicapavir**, an oral, direct-acting antiviral specifically targeting the N-protein, is being developed for the treatment of respiratory syncytial virus. As an N-protein inhibitor, Zelicapavir directly disrupts the ability of the virus to replicate, as compared to fusion inhibitors that work by preventing cells from becoming infected while allowing viral replication to continue.

This article is part of our premium content offering.Subscribe with a RTTNews subscription.

Subscribe Now

Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [ENTA.US](https://longbridge.com/en/quote/ENTA.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>](https://longbridge.com/en/news/286273737.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra]]>](https://longbridge.com/en/news/286601439.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)